# Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

> **NCT03229746** · PHASE4 · COMPLETED · sponsor: **Assiut University** · enrollment: 40 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** vincristine
- **DRUG:** azathioprine

## Key facts

- **NCT ID:** NCT03229746
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2018-06-01
- **Final completion:** 2018-06-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229746, "Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03229746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*